These targeted therapies include those already being successfully utilized in the treatment of B-ALL, including tyrosine kinase inhibitors for Ph+/Ph-like disease [63,64,65] and FLT3 inhibitors used in MLL-rearranged disease [12,66]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.